Black Diamond Therapeutics Inc. (BDTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
BDTX Stock Price Chart Interactive Chart >
BDTX Price/Volume Stats
| Current price | $1.67 | 52-week high | $14.18 |
| Prev. close | $1.54 | 52-week low | $1.46 |
| Day low | $1.48 | Volume | 159,200 |
| Day high | $1.68 | Avg. volume | 457,783 |
| 50-day MA | $2.56 | Dividend yield | N/A |
| 200-day MA | $5.49 | Market Cap | 60.61M |
Black Diamond Therapeutics Inc. (BDTX) Company Bio
Black Diamond Therapeutics, Inc. engages in the biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms. The company was founded by Dr. David M. Epstein and Dr. Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Latest BDTX News From Around the Web
Below are the latest news stories about Black Diamond Therapeutics Inc that investors may wish to consider to help them evaluate BDTX as an investment opportunity.
Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People OfficerCAMBRIDGE, Mass. and NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the appointment of Elizabeth Montgomery as its first Chief People Officer. Ms. Montgomery brings almost 20 years of global human resources leadership experience in the life sciences industry. In the newly created role, Ms. Montgomery will be a key member of the execu |
Will Black Diamond Therapeutics (NASDAQ:BDTX) Spend Its Cash Wisely?Just because a business does not make any money, does not mean that the stock will go down. For example, although... |
Black Diamond Therapeutics wins FDA nod to start clinical trial for cancer therapyBlack Diamond Therapeutics (BDTX) has added ~21.8% in the pre-market on above-average volume after announcing that the FDA cleared its investigational new drug ((IND)) application |
Black Diamond Therapeutics Announces FDA Allowance of IND Application for BDTX-1535, A MasterKey Inhibitor of EGFR for the Treatment of Gliobastoma and Non-Small Cell Lung CancerCAMBRIDGE, Mass. and NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for its MasterKey inhibitor BDTX-1535, an irreversible, mutant selective, brain-penetrant inhibitor of oncogenic mutations of epidermal growth factor receptor ( |
Black Diamond Therapeutics Announces Strategic Priorities and Expected Milestones for 2022Company announces IND submission for BDTX-1535 for the treatment of GBM and NSCLC including those with CNS tumors;Company to enroll additional patients into MasterKey-01 Phase 1 safety expansion cohort to obtain more clinical data and inform future development of BDTX-189;Company anticipates initiation of IND-enabling studies for its CNS-penetrant Class I,II,III BRAF program in 2022;Existing resources to be prioritized in the near-term for advancement of MasterKey pipeline programs BDTX-1535, BR |
BDTX Price Returns
| 1-mo | -31.28% |
| 3-mo | -46.82% |
| 6-mo | -72.17% |
| 1-year | -87.27% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -68.67% |
| 2021 | -83.37% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...